36% Avecho Share Price Move Prompts ASX Query

ASX Questions Avecho’s Sudden Trading Spike

Avecho Biotechnology Limited (ASX:AVE) has been unable to explain a roughly 36% move in its share price, after the ASX noted that the stock rose from $0.014 at the close on 20 October to $0.019 on 21 October, alongside a significant increase in trading volume.

The exchange’s price query asked whether Avecho knew of any undisclosed information that, if known by some investors, could account for the activity. Avecho answered no. It also said it had “no explanation” for the recent trading in its securities.

Company Confirms Continuous Disclosure Compliance

Avecho confirmed that it was complying with the ASX Listing Rules, including Listing Rule 3.1, which covers the disclosure of market-sensitive information. The response was authorised and approved by the company’s board.

That leaves the immediate market signal unresolved: the price and volume movement is documented, but the filing identifies no operational, clinical, financial or corporate event behind it. Avecho’s recent disclosure history has included progress in its Phase III insomnia trial, including the resumption of recruitment after an interim review, but today’s response does not connect that programme to the trading.

ASX Sets Out Halt and Suspension Options

The ASX correspondence warned that if a company cannot respond to a price query on time, or cannot immediately disclose information required under Listing Rule 3.1, it may need to discuss a trading halt. The exchange also said it would likely suspend Avecho’s securities if the company failed to respond by the specified deadline.

Avecho did respond within the requested window, so the filing itself does not announce a halt or suspension. The ASX nevertheless retains the right to release related correspondence and may take further action if later information raises fresh disclosure questions. For now, the key fact is less a new company development than the absence of one publicly identified.